Explore post-immunotherapy options for advanced squamous NSCLC, weighing docetaxel±ramucirumab, patient concerns, and why new trials matter.
Christian Rolfo, MD, PhD
Advertisement
Christian Rolfo, MD, PhD, is the director of the Division of Medical Oncology at The Ohio State University Comprehensive Cancer Center—James and a professor in the College of Medicine at The Ohio State University
Articles by Christian Rolfo, MD, PhD
When immunotherapy stops working in squamous NSCLC, clinicians weigh docetaxel±ramucirumab, weekly dosing, and clinical trials.
Drs Neal and Rolfo discuss the significance of the FDA approval of taletrectinib for the treatment of locally advanced or metastatic, ROS1-positive NSCLC.
Christian Diego Rolfo, MD, PhD, professor and unit coordinator at Antwerp University discusses the European perspective on precision medicine in lung cancer and the importance of clinical trials across different markets.
Advertisement
Latest Updated Articles
Second-Line Treatment in Squamous NSCLCSeptember 28th 2026
Dr. Rolfo on Precision Medicine in Lung CancerJanuary 11th 2017
Treatment Challenges in Squamous NSCLCSeptember 28th 2026
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Plinabulin Plus Docetaxel in Post-ICI Non-Squamous NSCLC
2
Breast Cancer Experts Highlight Abstracts to Watch at ESMO 2026
3
FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy
4
Navigating DLL3-Targeting T-Cell Engagers and the Evolving Small Cell Lung Cancer Treatment Landscape
5